INNV vs. VCYT, ARDT, ADUS, PGNY, NHC, PACS, GRAL, AHCO, TDOC, and VRDN
Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include Veracyte (VCYT), Ardent Health Partners (ARDT), Addus HomeCare (ADUS), Progyny (PGNY), National HealthCare (NHC), PACS Group (PACS), Grail (GRAL), AdaptHealth (AHCO), Teladoc Health (TDOC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry.
InnovAge vs. Its Competitors
Veracyte (NASDAQ:VCYT) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment.
Veracyte has a net margin of -2.18% compared to InnovAge's net margin of -3.19%. Veracyte's return on equity of 3.02% beat InnovAge's return on equity.
InnovAge has higher revenue and earnings than Veracyte. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
12.3% of InnovAge shares are held by institutional investors. 1.4% of Veracyte shares are held by insiders. Comparatively, 1.4% of InnovAge shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Veracyte has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
In the previous week, Veracyte had 4 more articles in the media than InnovAge. MarketBeat recorded 6 mentions for Veracyte and 2 mentions for InnovAge. Veracyte's average media sentiment score of 1.07 beat InnovAge's score of 0.94 indicating that Veracyte is being referred to more favorably in the media.
Veracyte currently has a consensus price target of $40.90, indicating a potential upside of 53.24%. InnovAge has a consensus price target of $5.00, indicating a potential upside of 35.50%. Given Veracyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veracyte is more favorable than InnovAge.
Veracyte received 452 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 73.02% of users gave Veracyte an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
Summary
Veracyte beats InnovAge on 13 of the 17 factors compared between the two stocks.
Get InnovAge News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InnovAge Competitors List
Related Companies and Tools
This page (NASDAQ:INNV) was last updated on 6/12/2025 by MarketBeat.com Staff
